JP2021524244A5 - - Google Patents

Info

Publication number
JP2021524244A5
JP2021524244A5 JP2020564908A JP2020564908A JP2021524244A5 JP 2021524244 A5 JP2021524244 A5 JP 2021524244A5 JP 2020564908 A JP2020564908 A JP 2020564908A JP 2020564908 A JP2020564908 A JP 2020564908A JP 2021524244 A5 JP2021524244 A5 JP 2021524244A5
Authority
JP
Japan
Prior art keywords
seq
chain variable
variable region
polypeptide sequence
heavy chain
Prior art date
Application number
JP2020564908A
Other languages
English (en)
Japanese (ja)
Other versions
JP7530298B2 (ja
JP2021524244A (ja
JPWO2019224711A5 (https=
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/IB2019/054182 external-priority patent/WO2019224711A2/en
Publication of JP2021524244A publication Critical patent/JP2021524244A/ja
Publication of JPWO2019224711A5 publication Critical patent/JPWO2019224711A5/ja
Publication of JP2021524244A5 publication Critical patent/JP2021524244A5/ja
Application granted granted Critical
Publication of JP7530298B2 publication Critical patent/JP7530298B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2020564908A 2018-05-24 2019-05-21 抗cd33抗体、抗cd33/抗cd3二重特異性抗体、及びその使用 Active JP7530298B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201862676123P 2018-05-24 2018-05-24
US62/676,123 2018-05-24
US201962825846P 2019-03-29 2019-03-29
US62/825,846 2019-03-29
PCT/IB2019/054182 WO2019224711A2 (en) 2018-05-24 2019-05-21 Anti-cd33 antibodies, anti-cd33/anti-cd3 bispecific antibodies and uses thereof

Publications (4)

Publication Number Publication Date
JP2021524244A JP2021524244A (ja) 2021-09-13
JPWO2019224711A5 JPWO2019224711A5 (https=) 2022-05-25
JP2021524244A5 true JP2021524244A5 (https=) 2022-05-25
JP7530298B2 JP7530298B2 (ja) 2024-08-07

Family

ID=67211770

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2020564908A Active JP7530298B2 (ja) 2018-05-24 2019-05-21 抗cd33抗体、抗cd33/抗cd3二重特異性抗体、及びその使用

Country Status (23)

Country Link
US (1) US11466082B2 (https=)
EP (1) EP3802606B1 (https=)
JP (1) JP7530298B2 (https=)
KR (1) KR102890653B1 (https=)
CN (1) CN112189022B (https=)
AU (1) AU2019274229B2 (https=)
BR (1) BR112020023357A2 (https=)
CL (1) CL2020003028A1 (https=)
CO (1) CO2020014575A2 (https=)
CR (1) CR20200567A (https=)
EC (1) ECSP20075198A (https=)
ES (1) ES2998890T3 (https=)
IL (1) IL278844A (https=)
JO (1) JOP20190116A1 (https=)
MA (1) MA52771A (https=)
MX (1) MX2020012588A (https=)
NI (1) NI202000088A (https=)
PE (1) PE20210180A1 (https=)
PH (1) PH12020552010A1 (https=)
SG (1) SG11202011210TA (https=)
TW (1) TW202033551A (https=)
UY (1) UY38242A (https=)
WO (1) WO2019224711A2 (https=)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2017015380A (es) 2015-05-29 2018-03-28 Amphivena Therapeutics Inc Metodos para utilizar proteinas de enlace biespecificas cd3 y cd33.
WO2018119142A1 (en) 2016-12-21 2018-06-28 Amgen Inc. Anti-tnf alpha antibody formulations
US11603405B2 (en) 2018-05-24 2023-03-14 Janssen Biotech, Inc. Anti-CD3 antibodies and uses thereof
MX2021002299A (es) 2018-08-31 2021-04-28 Alector Llc Anticuerpos de anti-cd33 y metodos para usarlos.
DE102018127845A1 (de) 2018-11-07 2020-05-07 Grimme Landmaschinenfabrik Gmbh & Co. Kg Verfahren zur Regelung des Betriebs einer Maschine zum Ernten von Hackfrüchten
AU2020225631A1 (en) 2019-02-22 2021-09-16 Memorial Sloan Kettering Cancer Center CD33 antibodies and methods of using the same to treat cancer
CN113766930B (zh) 2019-02-26 2025-07-22 特韦斯特生物科学公司 Glp1受体的变异核酸文库
IL293670A (en) 2019-12-09 2022-08-01 Twist Bioscience Corp Variable nucleic acid libraries for adenosine receptors
KR20220147631A (ko) * 2020-02-27 2022-11-03 얀센 바이오테크 인코포레이티드 면역 반응을 조절하기 위한 물질 및 방법
KR20220154728A (ko) * 2020-03-13 2022-11-22 얀센 바이오테크 인코포레이티드 Siglec-3/cd33을 결합시키기 위한 물질 및 방법
US20210284731A1 (en) * 2020-03-13 2021-09-16 Janssen Biotech, Inc. Methods and materials for modulating an immune response
IL296358A (en) * 2020-03-13 2022-11-01 Janssen Biotech Inc Materials and methods for modulating delta chain mediated immunity
WO2021202799A2 (en) 2020-03-31 2021-10-07 Fred Hutchinson Cancer Research Center Chimeric antigen receptors targeting cd33
WO2021202793A2 (en) * 2020-03-31 2021-10-07 Fred Hutchinson Cancer Research Center Chimeric antigen receptors targeting cd33
US20230190810A1 (en) * 2020-03-31 2023-06-22 Fred Hutchinson Cancer Center Anti-cd33 antibodies and uses thereof
CN113461817B (zh) * 2020-03-31 2025-04-18 苏州泽璟生物制药股份有限公司 一种抗人cd47抗体及其抗原结合片段、制备方法和应用
WO2021231237A2 (en) * 2020-05-11 2021-11-18 Augmenta Bioworks, Inc. Antibodies for sars-cov-2 and uses thereof
CN116249714A (zh) 2020-05-27 2023-06-09 詹森生物科技公司 包含cd3抗原结合结构域的蛋白质及其用途
EP4214233A1 (en) 2020-09-16 2023-07-26 Amgen Inc. Methods for administering therapeutic doses of bispecific t-cell engaging molecules for the treatment of cancer
WO2022159620A1 (en) * 2021-01-21 2022-07-28 Twist Bioscience Corporation Methods and compositions relating to adenosine receptors
IL305144A (en) 2021-02-16 2023-10-01 Janssen Pharmaceutica Nv Trispecific antibodies targeting BCMA, GPRC5D and CD3
TW202304988A (zh) 2021-03-24 2023-02-01 美商健生生物科技公司 靶向CD79b、CD20、及CD3之三特異性抗體
CN115443333B (zh) * 2021-04-27 2025-04-25 上海驯鹿生物技术有限公司 一种基因编辑的造血干细胞及其与car-t细胞的联合应用
EP4377354A4 (en) * 2021-07-30 2026-01-21 Nanjing Legend Biotech Co Ltd Anti-CD33 antibodies and their uses
AU2022340645A1 (en) * 2021-09-02 2024-02-29 Memorial Hospital For Cancer And Allied Diseases Anti-cd33 antibodies and uses thereof
WO2023037333A1 (en) * 2021-09-13 2023-03-16 Janssen Biotech, Inc CD33 X Vδ2 MULTISPECIFIC ANTIBODIES FOR THE TREATMENT OF CANCER
WO2023081898A1 (en) * 2021-11-08 2023-05-11 Alector Llc Soluble cd33 as a biomarker for anti-cd33 efficacy
AU2023367039A1 (en) * 2022-10-25 2025-05-15 Ablexis, Llc Anti-cd3 antibodies
WO2025120583A2 (en) * 2023-12-08 2025-06-12 Janssen Biotech, Inc. CD33 ANTIBODIES, CD33/Vδ2 MULTISPECIFIC ANTIBODIES AND USES THEREOF
WO2025149667A1 (en) 2024-01-12 2025-07-17 Pheon Therapeutics Ltd Antibody drug conjugates and uses thereof
WO2025174974A1 (en) * 2024-02-14 2025-08-21 Bristol-Myers Squibb Company Anti-cd33 antibodies and uses thereof
CN118221826B (zh) * 2024-04-25 2024-11-15 北京绿竹生物技术股份有限公司 一种结合人cd33和cd3的双特异性抗体
WO2026006492A2 (en) 2024-06-25 2026-01-02 Ypsilon Therapeutics, Inc. Anti-prame/hla-a2 antibodies and uses thereof
WO2026006495A1 (en) 2024-06-25 2026-01-02 Alloy Therapeutics, Inc. Anti-wt1/hla-a2 antibody and uses thereof
CN119804863B (zh) * 2025-03-13 2025-06-17 北京华诺泰生物医药科技有限公司 检测人偏肺病毒抗原的酶联免疫试剂盒及定量检测方法

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020142000A1 (en) 1999-01-15 2002-10-03 Digan Mary Ellen Anti-CD3 immunotoxins and therapeutic uses therefor
US6737056B1 (en) 1999-01-15 2004-05-18 Genentech, Inc. Polypeptide variants with altered effector function
BR0316101A (pt) 2002-11-07 2005-09-27 Immunogen Inc Anticorpos anticd33 e processo para tratamento de leucemia melóide aguda usando os mesmos
EP1789446A2 (en) 2004-09-02 2007-05-30 Genentech, Inc. Heteromultimeric molecules
EP3050963B1 (en) 2005-03-31 2019-09-18 Chugai Seiyaku Kabushiki Kaisha Process for production of polypeptide by regulation of assembly
DE102005028778A1 (de) 2005-06-22 2006-12-28 SUNJÜT Deutschland GmbH Mehrlagige Folie mit einer Barriere- und einer antistatischen Lage
AU2006301492B2 (en) 2005-10-11 2011-06-09 Amgen Research (Munich) Gmbh Compositions comprising cross-species-specific antibodies and uses thereof
WO2007147901A1 (en) 2006-06-22 2007-12-27 Novo Nordisk A/S Production of bispecific antibodies
RS53008B2 (sr) 2007-04-03 2022-12-30 Amgen Res Munich Gmbh Interspecijski specifičan cd3-epsilon vezujući domen
WO2008119565A2 (en) 2007-04-03 2008-10-09 Micromet Ag Cross-species-specific binding domain
WO2008119566A2 (en) 2007-04-03 2008-10-09 Micromet Ag Cross-species-specific bispecific binders
JP6126782B2 (ja) 2008-10-01 2017-05-10 アムゲン リサーチ (ミュンヘン) ゲーエムベーハー 異種間特異的psma×cd3二重特異性単鎖抗体
CA2738568C (en) 2008-10-01 2024-02-20 Micromet Ag Cross-species-specific single domain bispecific single chain antibody
PL2352763T5 (pl) 2008-10-01 2023-01-30 Amgen Research (Munich) Gmbh Bispecyficzne przeciwciała jednołańcuchowe o specyficzności wobec antygenów docelowych o dużej masie cząsteczkowej
JP2012525149A (ja) 2009-04-27 2012-10-22 オンコメッド ファーマシューティカルズ インコーポレイテッド ヘテロ多量体分子を作製するための方法
DK2560993T3 (da) 2010-04-20 2024-10-14 Genmab As Heterodimeric antibody fc-containing proteins and methods for production thereof
UA112062C2 (uk) 2010-10-04 2016-07-25 Бьорінгер Інгельхайм Інтернаціональ Гмбх Cd33-зв'язувальний агент
PL2635607T3 (pl) 2010-11-05 2020-05-18 Zymeworks Inc. Projekt stabilnego przeciwciała heterodimerowego z mutacjami w domenie FC
CA2854233C (en) 2011-11-04 2020-05-12 Zymeworks Inc. Stable heterodimeric antibody design with mutations in the fc domain
US20130309223A1 (en) * 2012-05-18 2013-11-21 Seattle Genetics, Inc. CD33 Antibodies And Use Of Same To Treat Cancer
HRP20231356T1 (hr) 2012-12-14 2024-02-16 Omniab, Inc. Polinukleotidi koji kodiraju protutijela glodavaca s ljudskim idiotipovima i životinje koje ih sadrže
AR097648A1 (es) 2013-09-13 2016-04-06 Amgen Inc Combinación de factores epigenéticos y compuestos biespecíficos que tienen como diana cd33 y cd3 en el tratamiento de leucemia mieloide
EA201691214A1 (ru) 2013-12-13 2016-12-30 Дженентек, Инк. Антитела к cd33 и иммуноконъюгаты
US9212225B1 (en) 2014-07-01 2015-12-15 Amphivena Therapeutics, Inc. Bispecific CD33 and CD3 binding proteins
JO3568B1 (ar) * 2014-09-05 2020-07-05 Janssen Pharmaceutica Nv عوامل ربط cd123 واستخداماتها
JP7497953B2 (ja) 2015-06-12 2024-06-11 アレクトル エルエルシー 抗cd33抗体及びその使用方法
JP7376977B2 (ja) 2015-06-12 2023-11-09 アレクトル エルエルシー 抗cd33抗体及びその使用方法
KR102733407B1 (ko) 2017-08-03 2024-11-21 알렉터 엘엘씨 항-cd33 항체 및 이의 이용 방법
EP3755348A4 (en) 2018-02-20 2022-03-02 Dragonfly Therapeutics, Inc. Antibody variable domains targeting cd33, and use thereof
US11603405B2 (en) * 2018-05-24 2023-03-14 Janssen Biotech, Inc. Anti-CD3 antibodies and uses thereof

Similar Documents

Publication Publication Date Title
JP2021524244A5 (https=)
JPWO2019224711A5 (https=)
JP2021514664A5 (https=)
IL276830B1 (en) Anti-claudin 18.2 antibodies and their uses
AU2016306090B2 (en) 5-bromo-2,6-di-(1H-pyrazol-l-yl)pyrimidin-4-amine for use in the treatment of cancer
JP2018534933A5 (https=)
CN114502591B (zh) 靶向bcma的抗体、双特异性抗体及其用途
JP2021524256A5 (https=)
JP2021526022A5 (https=)
JP2016505556A5 (https=)
JP2019531764A5 (https=)
JP2017529838A5 (https=)
JPWO2019173420A5 (https=)
RU2016137110A (ru) Антитела к компоненту комплемента с5
JP2017534256A5 (https=)
JPWO2019173291A5 (https=)
RU2010107175A (ru) Антитела человека к cd20 человека и способ их использования
JP2021510736A5 (https=)
JP2021528047A5 (https=)
RU2019139093A (ru) Фармацевтическая композиция на основе антитела к pd-l1 и ее применение
JP2020522280A5 (https=)
JP2020522281A5 (https=)
JP2021523100A5 (https=)
JP2021512652A5 (https=)
JP2021517459A5 (https=)